These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23649869)

  • 1. Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia.
    Hua J; Iwaki Y; Inoue M; Hagihara M
    Int J Hematol; 2013 Aug; 98(2):243-6. PubMed ID: 23649869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic-phase chronic myeloid leukemia with intracranial hemorrhage complicated with tumor lysis syndrome].
    Oyama C; Arakawa Y; Ikeda Y; Aoki T; Kubota Y; Isobe K; Mori M; Kurihara J; Koh K
    Rinsho Ketsueki; 2021; 62(5):346-351. PubMed ID: 34108312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
    Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
    Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib therapy in chronic myelogenous leukemia.
    Quintas-Cardama A; Cortes J
    Drugs Today (Barc); 2007 Oct; 43(10):691-702. PubMed ID: 17987222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nilotinib in patients with chronic myeloid leukemia without response to imatinib].
    Báez-de la Fuente E; Arellano-Severiano B
    Rev Med Inst Mex Seguro Soc; 2014; 52(3):330-3. PubMed ID: 24878095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
    Yamauchi T; Ueda T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
    Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
    Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
    Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
    Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
    Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
    Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
    Breccia M; Alimena G
    Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Jarkowski A; Sweeney RP
    Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
    Sasaki T; Franco OE; Ohishi K; Filipovich Y; Ishii K; Crawford SE; Takahashi N; Katayama N; Sugimura Y; Hayward SW
    Prostate; 2019 Feb; 79(3):259-264. PubMed ID: 30370673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
    Seki Y; Nagano O; Koda R; Morita S; Hasegawa G
    Int J Hematol; 2020 Oct; 112(4):584-591. PubMed ID: 32557125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.